Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2009 Oct 13;66(1):141–150. doi: 10.1007/s00280-009-1144-0

Figure 4.

Figure 4

X-DIM-C-pPhC6H5 activates PPARγ in Panc1 cells. (A) Activation of X-DIM-C-pPhC6H5. Panc1 cells were transfected with PPARγ-Gal4/pGal4 and treated with DMSO or different concentrations of X-DIM-C-pPhC6H5 (X=H, X=NO2, X=Br, X=OH, X=Me and X=OMe), and luciferase activity was determined as described in Materials and Methods. (B) Activation of PPARγ-active DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 and their 5,5'-dimethyl and 5.5'-dihydroxy derivatives. Panc1 cells were treated as described in (A), and luciferase activity was determined as described in Materials and Methods. Columns = mean of three replicate determinations for each treatment group; bars = SE; * = P < 0.05, significant induction. (C) Effects of PPARγ antagonist T007 on induced transactivation in Panc1 cells. Cells were transfected with PPARγ-GAL4/pGAL4, induction of luciferase activity by DIM-C-pPhC6H5 and the 5,5’-dihydroxy and 5,5'-dimethyl analogs was inhibited after cotreatment with 10 µM T007, a PPARγ antagonist. Columns = mean of three replicate determinations for each treatment group; bars = SE; * = P < 0.05, significant induction; ** = P < 0.05, significant inhibition.